ARCHIVES

Research Program For Biological Response Modifiers Outlined By DCT board Subcommittee

This article is from The Cancer Letter archive.

Vol. 05 No. 46 | November 16, 1979

Download PDF Visit The Full Archive

Related Articles

Letter to the Editor: Could Managed care Cause Drop In Accrual In Suramin Trial?

January 5, 1996

NCI To Voluntarily Spends $196 Million On Breast Cancer; Will Require Reallocation

November 13, 1992

FDA Approves Medication For Smoking Cessation

May 26, 2006

FDA Approves Xeloda For Breast Cancer Treatment.

September 28, 2001

Consensus Conference On Receptors Planned

June 22, 1979

An Unlucky Streak? Doctors Analyze Errors As Another Cancer Center Offers Apology

June 30, 1995